ScripPfizer and Astellas’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) could more than double the size of its addressable population if it can repeat the success it showed in combination with
In VivoMany pharmaceutical companies are scaling back their gene therapy investments, but Astellas is charting a different course. The Japanese giant has committed significantly to adeno-associated virus (AA
ScripBayer’s hopes of launching elinzanetant onto the US market this summer have been dashed by the US Food and Drug Administration which needs more to time to evaluate the company’s submission for the clo
In VivoThe pharmaceutical market is notoriously difficult to predict. Drug developers and the analysts who cover them must navigate a landscape shaped by geopolitical shifts, financial pressures and regulato